Log in to save to my catalogue

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and...

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1888684076

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial

About this item

Full title

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2017-06, Vol.389 (10087), p.2375-2382

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Summary Background Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selective NSAID plus proton-pump inhibitor is superior to a non-selective NSAID plus proton-pump inhibitor...

Alternative Titles

Full title

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1888684076

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1888684076

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(17)30981-9

How to access this item